Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
UK stocks were trading modestly lower by lunchtime on Monday amid thin trading on a US public holiday, with tonic water maker Fevertree Drinks tanking 25% on the back of disappointing trading update.
At 11.30, the benchmark FTSE 100 index was down 32.25 points, or 0.42%, at 7,642.31, while the FTSE 250 traded 38.4 points lower at 21,847.65.
LARGE AND MID CAP RISERS AND FALLERS
Fevertree Drinks sank 25% to £15 as it warned on profits, after subdued Christmas trading in the UK limited its annual revenue growth to a disappointing 10%.
Defence company BAE Systems rose 2.7% to 641.6p, on announcing that it had agreed to acquire Collins Aerospace's global positioning system business for $1.93bn.
BAE also agreed to acquire Raytheon's airborne tactical radios business for $275m.
Mining company Anglo American edged back 10p to £22.36 as it had made a formal £404.9m takeover bid for Sirius Minerals, which was accepted by the British fertilizer hopeful's board.
Sirius Minerals rose 2.2% to the 5.5p bid price.
SMALL CAP RISERS AND FALLERS
Mall operator Intu Properties slipped 8.6% to 20.9p after it revealed plans to conduct an equity raising.
Economic infrastructure financing specialist Sequoia Economic Infrastructure Fund fell 1.2% to 117.2p, as it too flagged a potential equity raise.
Online women's fashion retailer Sosandar reversed 6.2% to 26.5p, having warned that it would report a deeper-than-expected annual loss despite a jump in revenue, as it continued to invest in customer acquisition.
Waste-to-products group Renewi shed 5.9% to trade at 34.5p after warning that it would record a €25.5m exceptional charge in its annual results, owing to a new Dutch tax and Brexit hurting a key contract in Holland.
Advertising company M&C Saatchi softened 2p to 119p despite guiding for annual underlying profit in line with the downgraded guidance it delivered last month.
The company also said net cash would be least £15m, substantially ahead of expectations, owing to 'improved cash collection processes'.
Immunotherapy developer for cancer Scancell jumped 14.4% to 7.15p after it signed a collaboration and research agreement with a US-based, clinical-stage antibody company that it did not identify.
Cell-based therapies company MaxCyte rallied 9.1% to 132.5p on announcing that it was trading ahead of market expectations, as sales growth accelerated in the second half.
Advice-led wealth manager AFH Financial firmed 3.1% to 397p after reporting strong revenue growth, up 47% to £74.3m for the year to October, and assuring that trading remains strong and in line with the board's expectations.